Literature DB >> 21098646

Disposition and metabolism of cumene in F344 rats and B6C3F1 mice.

Ling-Jen Chen1, Christopher J Wegerski, Daniel J Kramer, Leslie A Thomas, Jacob D McDonald, Kelly J Dix, J Michael Sanders.   

Abstract

Cumene is a high-production volume chemical that has been shown to be a central nervous system depressant and has been implicated as a long-term exposure carcinogen in experimental animals. The absorption, distribution, metabolism, and excretion of [(14)C]cumene (isopropylbenzene) was studied in male rats and mice of both sexes after oral or intravenous administration. In both species and sexes, urine accounted for the majority of the excretion (typically ≥ 70%) by oral and intravenous administration. Enterohepatic circulation of cumene and/or its metabolites was indicated because 37% of the total dose was excreted in bile in bile duct-cannulated rats with little excreted in normal rats. The highest tissue (14)C levels in rats were observed in adipose tissue, liver, and kidney with no accumulation observed after repeat dosing up to 7 days. In contrast, mice contained the highest concentrations of (14)C at 24 h after dosing in the liver, kidney, and lung, with repeat dosing accumulation of (14)C observed in these tissues as well as in the blood, brain, heart, muscle, and spleen. The metabolites in the expired air, urine, bile, and microsomes were characterized with 16 metabolites identified. The volatile organics in the expired air comprised mainly cumene and up to 4% α-methylstyrene. The major urinary and biliary metabolite was 2-phenyl-2-propanol glucuronide, which corresponded with the main microsomal metabolite being 2-phenyl-2-propanol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098646      PMCID: PMC3061557          DOI: 10.1124/dmd.110.034769

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  28 in total

1.  Characterization of inhaled alpha-methylstyrene vapor toxicity for B6C3F1 mice and F344 rats.

Authors:  D L Morgan; J F Mahler; D T Kirkpatrick; H C Price; R W O'Connor; R E Wilson; M P Moorman
Journal:  Toxicol Sci       Date:  1999-02       Impact factor: 4.849

2.  A comparison of the acute behavioral effects of alkylbenzenes using a functional observational battery in mice.

Authors:  J S Tegeris; R L Balster
Journal:  Fundam Appl Toxicol       Date:  1994-02

3.  Lysosomal degradation of alpha 2u-globulin and alpha 2u-globulin-xenobiotic conjugates.

Authors:  L D Lehman-McKeeman; M I Rivera-Torres; D Caudill
Journal:  Toxicol Appl Pharmacol       Date:  1990-05       Impact factor: 4.219

4.  Stereoselective disposition of hydratropic acid in rat.

Authors:  T Yamaguchi; Y Nakamura
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

5.  NTP Toxicology and Carcinogenesis Studies of Ethylbenzene (CAS No. 100-41-4) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).

Authors: 
Journal:  Natl Toxicol Program Tech Rep Ser       Date:  1999-01

6.  Toxicological studies of certain alkylated benzenes and benzene; experiments on laboratory animals.

Authors:  M A WOLF; V K ROWE; D D MCCOLLISTER; R L HOLLINGSWORTH; F OYEN
Journal:  AMA Arch Ind Health       Date:  1956-10

7.  Enantioselective metabolism of cumene.

Authors:  T Ishida; T Matsumoto
Journal:  Xenobiotica       Date:  1992-11       Impact factor: 1.908

8.  Evaluation of potential modes of action of inhaled ethylbenzene in rats and mice.

Authors:  William T Stott; Keith A Johnson; Rainer Bahnemann; Susan J Day; Randal J McGuirk
Journal:  Toxicol Sci       Date:  2003-01       Impact factor: 4.849

Review 9.  Interpretation of male rat renal tubule tumors.

Authors:  I S Rodgers; K P Baetcke
Journal:  Environ Health Perspect       Date:  1993-12       Impact factor: 9.031

Review 10.  Alpha 2u-globulin nephropathy: review of the cellular and molecular mechanisms involved and their implications for human risk assessment.

Authors:  J A Swenberg
Journal:  Environ Health Perspect       Date:  1993-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.